Subscribe for full access
Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
N/A
1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL
Total Analysts: 0
Company Profile
Enochian Biosciences Inc. is a pre-clinical-stage biotechnology company. The Company is focused on developing allogeneic cell and gene therapies to promote stronger immune system responses for long-term or life-long cancer remission in cancers and to treat or cure infectious diseases, such as Human Immunodeficiency Virus (HIV) and Hepatitis B virus (HBV) infection. The Allogeneic Cell Therapy platform has a human immune system, which is designed to recognize the self and destroy otherness or non-self, such as bacteria, viruses and cancer cells. The Company’s product candidates include ENOB-HV-01, which utilizes a cellular- and immunotherapy approach that could provide both preventative and therapeutic vaccines for HIV and ENOB-DC-11, which is a genetically modified allogeneic dendritic cell therapeutic vaccine as product for long-term remission of solid tumors. It is also exploring ENOB-HV-21, a treatment for HIV with allogeneic natural killer (NK) and gamma delta t-cells (GDT).
We do our best to screen stocks as accurately as possible. Please let us know in the Community if you spot an error or find something questionable. Jazaak Allahu khairan.
